2 results
Approved WMORecruiting
To evaluate whether a faecal calprotectin guided strategy of anti-TNF dosing interval lengthening is non-inferior in maintaining remission in patients with IBD compared with an unchanged dosing interval.
Approved WMORecruiting
Part IPrimary: • To evaluate safety and tolerability of ODM-111 in single oral escalating doses compared to placeboSecondary: • To evaluate pharmacokinetics (PK) and pharmacodynamic (PD) effects of ODM-111 after administration of single escalating…